171 related articles for article (PubMed ID: 23821263)
1. A cellular replicon-based phenotyping assay to determine susceptibility of hepatitis C virus clinical isolates to NS3/4A protease inhibitors.
Vijgen L; Verbeeck J; Van Kerckhove B; Berke JM; Koletzki D; Fanning G; Lenz O
Methods Mol Biol; 2013; 1030():105-17. PubMed ID: 23821263
[TBL] [Abstract][Full Text] [Related]
2. Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitors.
Binder J; Tetangco S; Weinshank M; Maegley K; Lingardo L; Diehl W; Love R; Patick AK; Smith GJ
Antiviral Res; 2011 Aug; 91(2):102-11. PubMed ID: 21620899
[TBL] [Abstract][Full Text] [Related]
3. Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates.
Sheaffer AK; Lee MS; Hernandez D; Chaniewski S; Yu F; Falk P; Friborg J; Zhai G; McPhee F
Antivir Ther; 2011; 16(5):705-18. PubMed ID: 21817192
[TBL] [Abstract][Full Text] [Related]
4. Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates.
Qi X; Bae A; Liu S; Yang H; Sun SC; Harris J; Delaney W; Miller M; Mo H
Antiviral Res; 2009 Feb; 81(2):166-73. PubMed ID: 19063924
[TBL] [Abstract][Full Text] [Related]
5. Development and characterization of a replicon-based phenotypic assay for assessing HCV NS4B from clinical isolates.
Rajyaguru S; Yang H; Martin R; Miller MD; Mo H
Antiviral Res; 2013 Nov; 100(2):328-36. PubMed ID: 24013002
[TBL] [Abstract][Full Text] [Related]
6. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
Yu M; Corsa AC; Xu S; Peng B; Gong R; Lee YJ; Chan K; Mo H; Delaney W; Cheng G
Antiviral Res; 2013 Nov; 100(2):439-45. PubMed ID: 24013001
[TBL] [Abstract][Full Text] [Related]
7. Replication capacity of minority variants in viral populations can affect the assessment of resistance in HCV chimeric replicon phenotyping assays.
Verbinnen T; Jacobs T; Vijgen L; Ceulemans H; Neyts J; Fanning G; Lenz O
J Antimicrob Chemother; 2012 Oct; 67(10):2327-37. PubMed ID: 22723600
[TBL] [Abstract][Full Text] [Related]
8. Development of cell-based assays for in vitro characterization of hepatitis C virus NS3/4A protease inhibitors.
Chung V; Carroll AR; Gray NM; Parry NR; Thommes PA; Viner KC; D'Souza EA
Antimicrob Agents Chemother; 2005 Apr; 49(4):1381-90. PubMed ID: 15793116
[TBL] [Abstract][Full Text] [Related]
9. In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants.
Verbinnen T; Fevery B; Vijgen L; Jacobs T; De Meyer S; Lenz O
Antimicrob Agents Chemother; 2015 Dec; 59(12):7548-57. PubMed ID: 26392483
[TBL] [Abstract][Full Text] [Related]
10. Establishment of a robust hepatitis C virus replicon cell line over-expressing P-glycoprotein that facilitates analysis of P-gp drug transporter effects on inhibitor antiviral activity.
Hernandez D; Falk P; Yu F; Zhai G; Quan Y; Faria T; Cao K; Scola P; McPhee F
Biochem Pharmacol; 2013 Jan; 85(1):21-8. PubMed ID: 23063413
[TBL] [Abstract][Full Text] [Related]
11. Screening of hepatitis C virus inhibitors using genotype 1a HCV replicon cell lines.
Robinson M; Tian Y; Pagratis N; Delaney WE
Curr Protoc Microbiol; 2011 Aug; Chapter 17():Unit17.7. PubMed ID: 21805689
[TBL] [Abstract][Full Text] [Related]
12. Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity.
Bachmetov L; Gal-Tanamy M; Shapira A; Vorobeychik M; Giterman-Galam T; Sathiyamoorthy P; Golan-Goldhirsh A; Benhar I; Tur-Kaspa R; Zemel R
J Viral Hepat; 2012 Feb; 19(2):e81-8. PubMed ID: 22239530
[TBL] [Abstract][Full Text] [Related]
13. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).
Seiwert SD; Andrews SW; Jiang Y; Serebryany V; Tan H; Kossen K; Rajagopalan PT; Misialek S; Stevens SK; Stoycheva A; Hong J; Lim SR; Qin X; Rieger R; Condroski KR; Zhang H; Do MG; Lemieux C; Hingorani GP; Hartley DP; Josey JA; Pan L; Beigelman L; Blatt LM
Antimicrob Agents Chemother; 2008 Dec; 52(12):4432-41. PubMed ID: 18824605
[TBL] [Abstract][Full Text] [Related]
14. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
López-Labrador FX; Moya A; Gonzàlez-Candelas F
Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of protease-inhibitor-resistant hepatitis C virus replicons and infectious virus by intracellular intrabodies.
Gal-Tanamy M; Zemel R; Bachmatov L; Jangra RK; Shapira A; Villanueva RA; Yi M; Lemon SM; Benhar I; Tur-Kaspa R
Antiviral Res; 2010 Oct; 88(1):95-106. PubMed ID: 20705106
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus resistance to protease inhibitors.
Halfon P; Locarnini S
J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
[TBL] [Abstract][Full Text] [Related]
17. Development of a cell-based assay for high-throughput screening of inhibitors against HCV genotypes 1a and 1b in a single well.
Mondal R; Koev G; Pilot-Matias T; He Y; Ng T; Kati W; Molla A
Antiviral Res; 2009 Apr; 82(1):82-8. PubMed ID: 19174175
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of hepatitis C virus RNA replicons by peptide aptamers.
Trahtenherts A; Gal-Tanamy M; Zemel R; Bachmatov L; Loewenstein S; Tur-Kaspa R; Benhar I
Antiviral Res; 2008 Mar; 77(3):195-205. PubMed ID: 18243349
[TBL] [Abstract][Full Text] [Related]
19. Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6.
Imhof I; Simmonds P
J Virol; 2010 May; 84(9):4597-610. PubMed ID: 20164226
[TBL] [Abstract][Full Text] [Related]
20. Establishment of a subgenomic replicon for bovine viral diarrhea virus in Huh-7 cells and modulation of interferon-regulated factor 3-mediated antiviral response.
Horscroft N; Bellows D; Ansari I; Lai VC; Dempsey S; Liang D; Donis R; Zhong W; Hong Z
J Virol; 2005 Mar; 79(5):2788-96. PubMed ID: 15708997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
